{"id":53798,"date":"2023-05-22T15:39:39","date_gmt":"2023-05-22T10:09:39","guid":{"rendered":"http:\/\/finservwealth.com\/sun-pharma-advanced-research-company-falls-5-as-quarterly-loss-widens-to-rs-82-crore\/"},"modified":"2023-05-22T15:39:39","modified_gmt":"2023-05-22T10:09:39","slug":"sun-pharma-advanced-research-company-falls-5-as-quarterly-loss-widens-to-rs-82-crore","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/sun-pharma-advanced-research-company-falls-5-as-quarterly-loss-widens-to-rs-82-crore\/","title":{"rendered":"Sun Pharma Advanced Research Company falls 5% as quarterly loss widens to Rs 82 crore"},"content":{"rendered":"<p> There has been a significant increase in clinical trial expenses, product development expenses, and professional charges during the last quarter of financial year 2022-23.<\/p><div id=\"finse-1281377713\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/sun-pharma-advanced-research-company-falls-5-as-quarterly-loss-widens-to-rs-82-crore_17020201.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0There has been a significant increase in clinical trial expenses, product development expenses, and professional charges during the last quarter of financial year 2022-23. There has been a significant increase in clinical trial expenses, product development expenses, and professional charges during the last quarter of financial year 2022-23.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/sun-pharma-advanced-research-company-falls-5-as-quarterly-loss-widens-to-rs-82-crore_17020201.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> There has been a significant increase in clinical trial expenses, product development expenses, and professional charges during the last quarter of financial year 2022-23.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/sun-pharma-advanced-research-company-falls-5-as-quarterly-loss-widens-to-rs-82-crore_17020201.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0There has been a significant increase in clinical trial expenses, product development expenses, and professional charges during the last quarter of financial year 2022-23. There has been a significant increase in clinical trial expenses, product development expenses, and professional charges during the last quarter of financial year 2022-23.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/sun-pharma-advanced-research-company-falls-5-as-quarterly-loss-widens-to-rs-82-crore_17020201.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> There has been a significant increase in clinical trial expenses, product development expenses, and professional charges during the last quarter of financial year 2022-23.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-53798","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2023\/200x200\/p\/pharma-1_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/53798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=53798"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/53798\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=53798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=53798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=53798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}